litlas
Log inCreate account

Andreas K. Buck

Active 1991–2025

161
Papers
18,482
Citations
85
h-index
151
i10-index

Citations

Citations per year for Andreas K. Buck1984: 1 citations1993: 1 citations1996: 3 citations1997: 6 citations1998: 16 citations1999: 18 citations2000: 20 citations2001: 33 citations2002: 36 citations2003: 52 citations2004: 83 citations2005: 97 citations2006: 84 citations2007: 140 citations2008: 110 citations2009: 130 citations2010: 129 citations2011: 146 citations2012: 123 citations2013: 138 citations2014: 138 citations2015: 148 citations2016: 163 citations2017: 169 citations2018: 141 citations2019: 488 citations2020: 545 citations2021: 608 citations2022: 492 citations2023: 405 citations2024: 585 citations2025: 317 citations2026: 15 citations1985–1992: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,620 citing papers, 22.4% of this breakdownGermany: 944 citing papers, 13.1% of this breakdownChina: 524 citing papers, 7.3% of this breakdownItaly: 425 citing papers, 5.9% of this breakdownUnited Kingdom: 417 citing papers, 5.8% of this breakdownFrance: 314 citing papers, 4.3% of this breakdownSwitzerland: 304 citing papers, 4.2% of this breakdownNetherlands: 300 citing papers, 4.1% of this breakdownAustralia: 207 citing papers, 2.9% of this breakdownJapan: 207 citing papers, 2.9% of this breakdownCanada: 182 citing papers, 2.5% of this breakdownAustria: 142 citing papers, 2% of this breakdown
0%22.4%Other 22.6%

Institutions

Fields

  • Medicine82.4%
  • Biochemistry, Genetics and Molecular Biology10.9%
  • Neuroscience1.4%
  • Immunology and Microbiology1.3%
  • Engineering1.2%
  • Computer Science0.7%
  • Other2.1%

Topics

  • Medical Imaging Techniques and Applications7.2%
  • Radiopharmaceutical Chemistry and Applications5.8%
  • Prostate Cancer Treatment and Research4.3%
  • Radiomics and Machine Learning in Medical Imaging2.8%
  • Prostate Cancer Diagnosis and Treatment2.5%
  • Lymphoma Diagnosis and Treatment2.4%
  • Other75%

Coauthors

All papers

Open in search
  1. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

    Authors: Jan R. Dörr, Yong Yu, Maja Milanovic, Gregor Beuster, Christin Zasada, J. Henry M. Däbritz, Jan Lisec, Dido Lenze, Anne Gerhardt, Katharina Schleicher, Susanne Kratzat, Bettina Purfürst, Stefan Walenta, Wolfgang Mueller‐Klieser, Markus H. Gräler, Michael Hummel, Ulrich Keller, Andreas K. Buck, Bernd Dörken, Lothar Willmitzer, Maurice Reimann, Stefan Kempa, Soyoung Lee, Clemens A. Schmitt - Nature 2013 cited by 539

  2. Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

    Authors: Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Ruth Seggewiß-Bernhardt, Barbara Deschler-Baier, Manik Chatterjee, Maria-Elisabeth Goebeler, Kurt Miller, Maria De Santis, Wolfgang Loidl, Christian Dittrich, Andreas K. Buck, Constantin Lapa, Annette Thurner, Sabine Wittemer‐Rump, Gökben Koca, Oliver Boix, Wolf‐Dietrich Döcke, Ricarda Finnern, Helena Kusi, Antoinette Ajavon‐Hartmann, Sabine Stienen, Cyrus Sayehli, Bülent Polat, Ralf C. Bargou - Immunotherapy 2020 cited by 144

  3. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells

    Authors: Max G. Bachem, Marion Schünemann, Marco Ramadani, Marco Siech, H. G. Beger, Andreas K. Buck, Shaoxia Zhou, Alexandra Schmid‐Kotsas, Guido Adler - Gastroenterology 2005 cited by 641

  4. Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days

    Authors: Heribert Hänscheid, Constantin Lapa, Andreas K. Buck, Michael Laßmann, Rudolf A. Werner - Journal of Nuclear Medicine 2017 cited by 216

  5. Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

    Authors: Kerstin Michalski, Juri Ruf, Christian Goetz, Anna Katharina Seitz, Andreas K. Buck, Constantin Lapa, Philipp E. Hartrampf - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 118

  6. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

    Authors: Ken Herrmann, Margret Schottelius, Constantin Lapa, Theresa Osl, Andreas Poschenrieder, Heribert Hänscheid, Katharina Lückerath, Martin Schreder, Christina Bluemel, Markus Knott, Ulrich Keller, Andreas Schirbel, Samuel Samnick, Michael Laßmann, Saskia Kropf, Andreas K. Buck, Hermann Einsele, Hans‐Juergen Wester, Stefan Knop - Journal of Nuclear Medicine 2015 cited by 269

  7. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma

    Authors: Britta Heinze, Carmina Teresa Fuß, Paolo Mulatero, Felix Beuschlein, Martín Reincke, Mona Mustafa, Andreas Schirbel, Timo Deutschbein, Tracy Ann Williams, Yara Rhayem, Marcus Quinkler, Nada Rayes, Silvia Monticone, Vanessa Wild, Celso E. Gómez-Sánchez, Anna‐Carinna Reis, Stephan Petersenn, Hans‐Juergen Wester, Saskia Kropf, Martin Faßnacht, Katharina Lang, Ken Herrmann, Andreas K. Buck, Christina Bluemel, Stefanie Hahner - Hypertension 2017 cited by 166

  8. CXCR4-targeted theranostics in oncology

    Authors: Andreas K. Buck, Sebastian E. Serfling, Thomas Lindner, Heribert Hänscheid, Andreas Schirbel, Stefanie Hahner, Martin Faßnacht, Hermann Einsele, Rudolf A. Werner - European Journal of Nuclear Medicine and Molecular Imaging 2022 cited by 123

  9. Long-Term Nephrotoxicity of177Lu-PSMA Radioligand Therapy

    Authors: Lisa Steinhelfer, Lukas Lunger, Lisena Cala, Christian H. Pfob, Constantin Lapa, Philipp E. Hartrampf, Andreas K. Buck, Hannah Schäfer, Christoph Schmaderer, Robert Tauber, Julia Brosch-Lenz, Bernhard Haller, Valentin H. Meissner, Karina Knorr, Wolfgang Weber, Matthias Eiber - Journal of Nuclear Medicine 2023 cited by 64

  10. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values

    Authors: Constantin Lapa, Martin Schreder, Andreas Schirbel, Samuel Samnick, K. Martin Kortüm, Ken Herrmann, Saskia Kropf, H. Einsele, Andreas K. Buck, Hans‐Jürgen Wester, Stefan Knop, Katharina Lückerath - Theranostics 2016 cited by 196

  11. 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

    Authors: Rudolf A. Werner, Thorsten Derlin, Constantin Lapa, Sara Sheikbahaei, Takahiro Higuchi, Frederik L. Giesel, Spencer C. Behr, Alexander Drzezga, Hiroyuki Kimura, Andreas K. Buck, Frank M. Bengel, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe - Theranostics 2019 cited by 160

  12. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using 68Ga-PentixaFor PET

    Authors: Andreas K. Buck, Alexander Haug, Niklas Dreher, Alessandro Lambertini, Takahiro Higuchi, Constantin Lapa, Alexander Weich, Martin G. Pomper, Hans‐Jürgen Wester, Anja Zehnder, Andreas Schirbel, Samuel Samnick, Marcus Hacker, Verena Pichler, Stefanie Hahner, Martin Faßnacht, Hermann Einsele, Sebastian E. Serfling, Rudolf A. Werner - Journal of Nuclear Medicine 2022 cited by 86

  13. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

    Authors: Philipp E. Hartrampf, Franz‐Xaver Weinzierl, Andreas K. Buck, Steven P. Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert Kübler, Andreas Schirbel, Markus Essler, Ralph A. Bundschuh, Rudolf A. Werner - European Journal of Nuclear Medicine and Molecular Imaging 2022 cited by 53

  14. Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors

    Authors: Aleksander Kosmala, Sebastian E. Serfling, Wiebke Schlötelburg, Thomas Lindner, Kerstin Michalski, Andreas Schirbel, Takahiro Higuchi, Philipp E. Hartrampf, Andreas K. Buck, Alexander Weich, Rudolf A. Werner - Clinical Nuclear Medicine 2022 cited by 42

  15. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

    Authors: Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra, Felix M. Mottaghy, Markus Dietlein, Ali Guermazi, Gregory A. Wiseman, Lale Kostakoğlu, Klemens Scheidhauer, Andreas K. Buck, Ralph Naumann, Karoline Spaepen, Rodney J. Hicks, Wolfgang Weber, Sven N. Reske, Markus Schwaiger, Lawrence H. Schwartz, Josée M. Zijlstra, Barry A. Siegel, Bruce D. Cheson - Journal of Clinical Oncology 2007 cited by 1,336

  16. Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy?

    Authors: Martin M. Reich, Joachim Brumberg, Nicoló Gabriele Pozzi, Giorgio Marotta, Jonas Roothans, Mattias Åström, Thomas Musacchio, Leonardo Lopiano, Michele Lanotte, Ralph Lehrke, Andreas K. Buck, Jens Volkmann, Ioannis U. Isaias - Brain 2016 cited by 160

  17. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma

    Authors: Constantin Lapa, Ken Herrmann, Andreas Schirbel, Heribert Hänscheid, Katharina Lückerath, Margret Schottelius, Malte Kircher, Rudolf A. Werner, Martin Schreder, Samuel Samnick, Saskia Kropf, Stefan Knop, Andreas K. Buck, Hermann Einsele, Hans‐Juergen Wester, K. Martin Kortüm - Theranostics 2017 cited by 153

  18. Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor

    Authors: Ken Herrmann, Constantin Lapa, Hans‐Juergen Wester, Margret Schottelius, Christiaan Schiepers, Uta Eberlein, Christina Bluemel, Ulrich Keller, Stefan Knop, Saskia Kropf, Andreas Schirbel, Andreas K. Buck, Michael Laßmann - Journal of Nuclear Medicine 2015 cited by 135

  19. Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on 68Ga-Pentixafor PET/CT Imaging Using Deep Learning Methods

    Authors: Lina Xu, Giles Tetteh, Jana Lipková, Yu Zhao, Hongwei Li, Patrick Ferdinand Christ, Marie Piraud, Andreas K. Buck, Kuangyu Shi, Bjoern Menze - Contrast Media & Molecular Imaging 2018 cited by 131

  20. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma

    Authors: Constantin Lapa, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, Gerd Wunderlich, Rudolf A. Werner, Samuel Samnick, Jörg Kotzerke, Hermann Einsele, Andreas K. Buck, Hans‐Jürgen Wester, Götz Ulrich Grigoleit - Journal of Nuclear Medicine 2018 cited by 105

  21. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

    Authors: Kathrin Philipp‐Abbrederis, Ken Herrmann, Stefan Knop, Margret Schottelius, Matthias Eiber, Katharina Lückerath, Elke Pietschmann, Stefan Habringer, Carlos Gerngroß, Katharina Franke, Martina Rudelius, Andreas Schirbel, Constantin Lapa, Kristina Schwamborn, Sabine Steidle, Elena Hartmann, Andreas Rosenwald, Saskia Kropf, Ambros J. Beer, Christian Peschel, Hermann Einsele, Andreas K. Buck, Markus Schwaiger, Katharina S. Götze, Hans‐Jürgen Wester, Ulrich Keller - EMBO Molecular Medicine 2015 cited by 213

  22. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

    Authors: Michael C. Kreißl, Heribert Hänscheid, Mario Löhr, Frederik A. Verburg, Markus Schiller, Michael Laßmann, Christoph Reiners, Samuel Samnick, Andreas K. Buck, Michael Flentje, Reinhart A. Sweeney - Radiation Oncology 2012 cited by 96

  23. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics

    Authors: Stefan Habringer, Constantin Lapa, Peter Herhaus, Margret Schottelius, Rouzanna Istvánffy, Katja Steiger, Julia Slotta‐Huspenina, Andreas Schirbel, Heribert Hänscheid, Stefan Kircher, Andreas K. Buck, Katharina S. Götze, Binje Vick, Irmela Jeremias, Markus Schwaiger, Christian Peschel, Robert A.J. Oostendorp, Hans‐Jürgen Wester, Götz-Ulrich Grigoleit, Ulrich Keller - Theranostics 2017 cited by 105

  24. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T

    Authors: Philipp E. Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, Hubert Kübler, Sebastian E. Serfling, Wiebke Schlötelburg, Kerstin Michalski, Steven P. Rowe, Martin G. Pomper, Andreas K. Buck, Uta Eberlein, Rudolf A. Werner - European Journal of Nuclear Medicine and Molecular Imaging 2023 cited by 37